|
|
Article: Landmark Serzone Chronic Depression Study Offers Great Hope For People Suffering From Depression.
- Article from:
- PR Newswire
- Article date:
- May 18, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Largest Study Ever To Compare Efficacy of Medication, Psychotherapy and
The Combination of the Two in the Treatment of Chronic Depression
PRINCETON, N.J., May 18 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that Martin Keller, M.D., chief study investigator and Mary E. Zucker, Professor and Chairman of the department of psychiatry and human behavior, Brown University School of Medicine, Providence, RI, presented new research findings from the acute phase of the landmark Serzone(R) (nefazodone HCl) Chronic Depression Study. The study demonstrates that combination therapy with Serzone and a form of psychotherapy developed for ...